From: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
APE1
Median (range)
PARP1
XRCC1
Stable disease/Partial response
(n = 7)
32.45 (0.01–176.7)
0.5 (0.001–2.63)
0.2 (0.008–1.05)
Progression
47.18 (4.48–87.73)
1.36 (0.01–26.17)
0.58 (0.04–1.26)